Our novel immunohistochemical scoring system, alongside the categorization of tumor differentiation patterns, has not only revealed a significant link between the diversity of CDX2 expression and the heterogeneity of colon cancer differentiation but also provided a new lens through which to view the evaluation of colon tumors. Here, CDX2 is linked to malignant colon neoplasm.